NCIC Clinical Trials Group, Cancer Research Institute, Queen's University, 10 Stuart Street, Kingston, Ontario K7L 3N6, Canada.
Oncologist. 2012;17(3):384-7. doi: 10.1634/theoncologist.2011-0324. Epub 2012 Feb 14.
Interferon is the only accepted adjuvant treatment for patients with melanoma; hence, oncologists should be aware of the possibility of retinal abnormalities resulting from its use. Interferon-associated retinopathy in patients being treated for resected melanoma is a rare phenomenon with a proposed immunological basis. Patients are usually asymptomatic or have mild visual impairments, with cotton wool infarcts and hemorrhages. These symptoms and signs usually resolve with the discontinuation of interferon, but in a few severe presentations the visual impairments and retinal changes can be irreversible.
干扰素是治疗黑色素瘤患者唯一被认可的辅助治疗药物；因此，肿瘤学家应该意识到其使用可能导致视网膜异常。接受切除黑色素瘤治疗的患者发生干扰素相关性视网膜病变是一种罕见现象，其发病机制可能与免疫有关。患者通常无明显症状或仅有轻微视力障碍，表现为棉絮状梗塞和出血。这些症状和体征通常在停止使用干扰素后会缓解，但在少数严重的情况下，视力障碍和视网膜变化可能是不可逆的。
